MarketCapExport financials
Celyad Oncology SA (CYAD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Celyad Oncology SA Balance Sheet 2022-2011 | CYAD
Brief overview of Celyad Oncology SA's balance sheet strength
This overview follows the five latest available annual observations between 2016 and 2020.
Across five reporting periods, assets decreased -52.4%, from €138.8 million to €66.1 million, producing a negative trend.
Asset growth of -52.4% came with a -26.8% rise in liabilities. Financial leverage became more prominent.
The equity ratio is 46.9% versus 65.5% five periods ago. Capitalization remains workable.
The period ended with net cash: net debt stood at -€13.6 million. This supports financial flexibility.
The cash share moved from 34.8% to 26.1%. A higher figure generally provides more room in an adverse scenario.
Retained earnings are negative at -€283 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Overall assessment
Celyad Oncology SA's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet Celyad Oncology SA
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-12.2 M | -27.4 M | -13.6 M | -35.2 M | -39.4 M | -19.5 M | -45 M | -99.5 M | -27.2 M | -19 M | -585 K | 116 K |
Long Term Debt |
118 K | 1.73 M | 2.52 M | 2.97 M | 652 K | 3.76 M | 3.38 M | - | - | - | 812 K | - |
Long Term Debt Current |
137 K | 902 K | 1.08 M | 1.17 M | 484 K | - | - | - | - | - | - | - |
Total Non Current Liabilities |
4.97 M | 22.5 M | 23.3 M | 32.3 M | 29.1 M | 22.1 M | 36.6 M | 36.6 M | 11.2 M | 12.1 M | 12.3 M | 116 K |
Total Liabilities |
- | - | 35.1 M | 44.2 M | 38.7 M | 30.1 M | 47.9 M | 48.1 M | 17.3 M | 15.5 M | 15.1 M | 6.04 M |
Deferred Revenue |
- | - | 2.21 M | 346 K | 276 K | 226 K | 1.11 M | 898 K | 777 K | 428 K | - | - |
Retained Earnings |
-350 M | -309 M | -283 M | -74.4 M | -218 M | -180 M | -124 M | -100 M | -71.2 M | -36.4 M | -11.3 M | -9.13 M |
Total Assets |
19.7 M | 79.9 M | 66.1 M | 89.8 M | 94.3 M | 77.6 M | 139 M | 160 M | 44 M | 32.4 M | 13.7 M | 6.88 M |
Cash and Cash Equivalents |
12.4 M | 30 M | 17.2 M | 39.3 M | 40.5 M | 23.3 M | 48.4 M | 100 M | - | - | - | - |
Book Value |
19.7 M | 79.9 M | 31 M | 45.6 M | 55.6 M | 47.5 M | 90.9 M | 111 M | 26.7 M | 16.9 M | -1.31 M | 840 K |
Total Shareholders Equity |
4.32 M | 43.6 M | 31 M | 45.6 M | 55.6 M | 47.5 M | 90.9 M | 111 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Quarterly Balance Sheet Celyad Oncology SA
| 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
351 K | 118 K | - | 1.38 M | - | 1.73 M | - | 2.1 M | - | 2.52 M | - | 2.51 M | - | 2.97 M | - | 3.4 M | - | 652 K | - | - | - | 3.76 M | - | - | - | 3.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
5.07 M | 4.97 M | - | 21.1 M | - | 22.5 M | - | 25.3 M | - | 23.3 M | - | 34.6 M | - | 32.3 M | - | 31.5 M | - | 29.1 M | - | - | - | 22.1 M | - | - | - | 36.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-354 M | -350 M | - | -323 M | - | -309 M | - | -63.3 M | - | -283 M | - | -91 M | - | -74.4 M | - | -61.5 M | - | -218 M | - | - | - | -180 M | - | - | - | -124 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
12.2 M | 19.7 M | - | 63.1 M | - | 79.9 M | - | 62.7 M | - | 66.1 M | - | 75.8 M | - | 89.8 M | - | 81.4 M | - | 94.3 M | - | - | - | 77.6 M | - | - | - | 139 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
4.98 M | 12.4 M | - | 14.4 M | - | 30 M | - | 12 M | - | 17.2 M | - | 26.7 M | - | 39.3 M | - | 33.7 M | - | 40.5 M | - | 62.4 M | - | 23.3 M | - | - | - | 48.4 M | - | - | - | 100 M | - | - | - | 27.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
12.2 M | 19.7 M | - | 63.1 M | - | 79.9 M | - | 62.7 M | - | 66.1 M | - | 75.8 M | - | 89.8 M | - | 81.4 M | - | 94.3 M | - | - | - | 77.6 M | - | - | - | 139 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.02 M | 4.32 M | - | 30.6 M | - | 43.6 M | - | 24.9 M | - | 31 M | - | 30.3 M | - | 45.6 M | - | 40.9 M | - | 55.6 M | - | 72.7 M | - | 47.5 M | - | - | - | 90.9 M | - | - | - | 111 M | - | - | - | 26.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Balance Sheet is a fundamental financial report of Celyad Oncology SA, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Danmark
Canada
Singapore
Irlanda
Britain
